ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

ipsen pharma - cabozantinib - neoplazme štitnjače - antineoplastična sredstva - liječenje odraslih bolesnika s progresivnim, neosjetljivim lokalno naprednim ili metastaznim karcinomom medularnog štitnjače.

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

ipsen pharma - mecasermin - laronov sindrom - hipofiza i hipotalamusni hormoni i analozi - za dugotrajno liječenje zatajenja rasta u djece i adolescenata s teškim primarne inzulin-kao-rasta-faktor-1 nedostatak (primarni igfd). teška primarne igfd određuje:standardna visina odstupanja rezultat ≤ -3. 0;bazalni inzulin-sličan faktor rasta-1 (igf-1) razine ispod 2. 5. percentile za dob i spol;hormon rasta (gh) adekvatnost;iznimka je sekundarni oblik igf-1 deficit, kao što su гипотрофия, hipotireoza, ili kronični tretman farmakološke doze anti steroida. izražene igfd uključuje bolesnika s mutacije u genu gr receptor (usd), stup-blaženstvo signalnog putu, i igf-1, gen nedostatke; oni ne gh nedovoljan, i tako oni ne mogu odgovoriti adekvatno экзогенным hormon rasta, liječenje. preporučljivo je potvrditi dijagnozu, provode test igf-1 generacija .

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

ipsen pharma - somatropin - turner syndrome; dwarfism, pituitary - hipofiza i hipotalamusni hormoni i analozi - dugoročno liječenje djece s neuspjehom rasta zbog neadekvatne endogene sekrecije hormona rasta. dugotrajno liječenje zatajenja rasta povezane s turnerovim sindromom. liječenje kod djece u препубертатном dobi s povećanjem srca, povezana s kroničnom bubrežnom insuficijencijom do transplantacije bubrega. zamjena endogenog hormona rasta kod odraslih osoba s nedostatkom hormona rasta ili dječjoj ili odrasloj dobi etiologije. nedostatak hormona rasta mora biti na odgovarajući način potvrđena prije početka liječenja.

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastična sredstva - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

ipsen pharma, 65 quai georges gorse, boulogne-billancourt, francuska - neurotoksin clostridium botulinum tip a - hemaglutininski kompleks - otopina za injekciju - urbroj: 125 speywood jedinica botulinskog toksina tipa a u 0,625 ml otopine u bočici

ক্রোয়েশিয়া - ক্রোয়েশীয় - HALMED (Agencija za lijekove i medicinske proizvode)

ipsen pharma, 65 quai georges gorse, boulogne-billancourt, francuska - neurotoksin clostridium botulinum tip a - hemaglutininski kompleks - prašak za otopinu za injekciju - urbroj: 125 speywood jedinica botulinskog toksina tipa a u prašku u bočici

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

ipsen pharma - palovarotene - myositis ossificans - ostali lijekovi za poremećaje mišićno-koštanog sustava - treatment of fibrodysplasia ossificans progressiva.

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

novartis europharm limited - travoprost - ocular hypertension; glaucoma, open-angle - ophthalmologicals, antiglaucoma preparations and miotics - smanjenje povišenog intraokularnog tlaka kod odraslih bolesnika s okularnom hipertenzijom ili glaukomom otvorenog kuta (vidjeti odjeljak 5. smanjenje povećanog od intraokularna tlaka u pedijatrijski bolesnici u dobi od 3 godine < 18 godina sa očni hipertenzije ili dijete glaukoma.

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

novartis europharm limited - travoprost - glaucoma, open-angle; ocular hypertension - ophthalmologicals - smanjenje povišenog intraokularnog tlaka kod odraslih bolesnika s okularnom hipertenzijom ili glaukomom otvorenog kuta (vidjeti odjeljak 5. pad od intraokularna veliki pritisak kada pedijatrijska bolesnika u dobi od 2 mjeseca do < 18 godina sa očni hipertenzije ili dijete glaukom (vidi odjeljak 5.

ইউরোপীয় ইউনিয়ন - ক্রোয়েশীয় - EMA (European Medicines Agency)

bayer ag - rivaroksaban - arthroplasty, replacement; venous thromboembolism - antitrombotska sredstva - xarelto, uvedene zajedno sa ацетилсалициловой kiselinom (ask) sami ili sa asc plus клопидогрел ili Тиклопидин, prikazana za prevenciju атеротромботических događaja kod odraslih pacijenata nakon akutnog koronarni sindrom (acs) s povišenom razinom кардиальных biomarkera. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. prevencija venske tromboembolije (vte) u odraslih bolesnika koji se podvrgavaju izborni operacije zamjena kuka ili koljena. liječenje tromboze dubokih vena (dvt) i plućne embolije (ТЭЛА) i prevenciju recidiva dvt i ТЭЛА kod odraslih. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.